HMGB1-derived peptide acts as adjuvant inducing immune responses to peptide and protein antigen
Contribuinte(s) |
UNIVERSIDADE DE SÃO PAULO |
---|---|
Data(s) |
19/10/2012
19/10/2012
2010
|
Resumo |
There is a need for new adjuvants that will induce immune responses to subunit vaccines. We show that a short peptide, named Hp91, whose sequence corresponds to an area within the endogenous molecule high mobility group box (HMGB1) protein 1 potentiates cellular immune responses to peptide antigen and cellular and humoral immune responses to protein antigen in vivo. Hp91 promoted the in vivo production of the immunomodulatory cytokines, IFN-gamma, TNF-alpha, IL-6, and IL-12 (p70), as well as antigen-specific activation of CD8+ T cells. These results demonstrate the ability of a short immunostimulatory peptide to serve as an adjuvant for subunit vaccines. (C) 2010 Elsevier Ltd. All rights reserved. National Institutes of Health (NCI/NIH)[5 U54 CA119335] Swedish Research Council[AI52731] Swedish International Development Cooperation Agency SIDA VINNMER (Vinnova) |
Identificador |
VACCINE, v.28, n.47, p.7556-7562, 2010 0264-410X http://producao.usp.br/handle/BDPI/24114 10.1016/j.vaccine.2010.08.054 |
Idioma(s) |
eng |
Publicador |
ELSEVIER SCI LTD |
Relação |
Vaccine |
Direitos |
restrictedAccess Copyright ELSEVIER SCI LTD |
Palavras-Chave | #HMGB-1 peptides #Adjuvants #Vaccine #Immunotherapy #Dendritic cells #TOLL-LIKE RECEPTORS #MOBILITY GROUP BOX-1 #PLASMACYTOID DENDRITIC CELLS #GLYCATION END-PRODUCTS #TUMOR-NECROSIS-FACTOR #VACCINE ADJUVANTS #FUTURE-PROSPECTS #NECROTIC CELLS #CPG DNA #HMGB1 #Immunology #Medicine, Research & Experimental |
Tipo |
article original article publishedVersion |